Abivax’s Covid-19 Phase 2b/3 miR-AGE trial with ABX464 declared Research National Priority by …,

Abivax’s lead drug-candidate ABX464 has shown in clinical and preclinical studies that it may have a potentially beneficial triple effect for the treatment …, Abivax’s lead drug-candidate ABX464 has shown in clinical and preclinical studies that it may have a potentially beneficial triple effect for the treatment …, Read More

Scroll to Top